- Home
- AQST vs AUTL Comparison
AQST vs AUTL Comparison
Compare AQST & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AQST | AUTL |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.4M | 596.2M |
| IPO Year | 2007 | 2025 |
Fundamental Metrics
Financial Performance| Metric | AQST | AUTL |
|---|---|---|
| Price | $4.63 | $1.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $9.33 | $8.73 |
| AVG Volume (30 Days) | ★ 2.1M | 1.5M |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $67,430,000.00 | $10,120,000.00 |
| Revenue This Year | $12.09 | $98.68 |
| Revenue Next Year | $35.73 | $28.47 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 0.77 | ★ 496.00 |
| 52 Week Low | $2.94 | $1.18 |
| 52 Week High | $7.55 | $2.58 |
Technical Indicators
Market Signals| Indicator | AQST | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 47.09 | 38.37 |
| Support Level | $4.51 | $1.37 |
| Resistance Level | $4.69 | $1.92 |
| Average True Range (ATR) | 0.22 | 0.09 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 28.36 | 18.57 |
Price Performance
Historical ComparisonAbout AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.